As of January 2026, Health Canada’s Regulatory Enrolment Process (REP) is mandatory for all Class II, III, and IV medical device licence (MDL) applications. This change, signalled since REP’s voluntary launch for medical devices in July 2024, fundamentally reshapes how manufacturers prepare and file applications. PDF forms are out. Manufacturers must now use structured XML templates, submit electronically through the Common Electronic Submissions Gateway (CESG), and complete a sequence of enrolment steps before filing any application.
For manufacturers with active submissions or devices in the pipeline, this is not a procedural footnote. The full intake process has changed. Health Canada will not accept applications that fall outside REP requirements.
What REP Replaces and Why the Change Was Made
Before REP, manufacturers submitted MDL applications for Class II, III, and IV devices using Health Canada PDF forms, often delivered by email or physical media. The system worked, but it was manual, inconsistent, and difficult to integrate with Health Canada’s internal review systems.
REP replaces those forms with structured XML templates that standardise how Health Canada captures company, dossier, and application information. Because REP files are machine-readable, data flows directly into Health Canada’s systems rather than requiring manual re-entry. The result: faster administrative processing, fewer screening errors, and a more consistent intake experience across submissions.
Routing all submissions through CESG also eliminates the security risks that came with emailing confidential regulatory dossiers.
The Four-Step Enrolment Sequence
REP for medical devices is not a single form. It is a structured process that manufacturers must complete in the correct order. Skipping a step, or filing before completing enrolment, will result in rejections at screening.
Step 1 – Company Enrolment
Complete the Company (CO) Template to obtain a Company ID and Contact IDs from Health Canada. Submit this template by email as a draft XML file. Health Canada returns a final CO XML file with the assigned identifiers. Store it carefully; those IDs are required for every subsequent step and for all future registrations and amendments.
Step 2 – Dossier ID Request
Once Health Canada confirms your Company ID, request a Dossier ID for each device or device family using the Dossier ID Request Form. This is the only authorised method for obtaining this identifier. Health Canada recommends submitting the request no more than eight weeks before filing. Each new regulatory activity requires its own Dossier ID.
Step 3 – Regulatory Transaction Template
Complete the Regulatory Transaction (RT) Template for every regulatory transaction submitted to Health Canada. Certain transaction types also require an Application Information (AI) Template.
Step 4 – Device Details and CESG Submission
All new licence applications, and applicable amendment applications that affect a manufacturer’s catalogue listing, must include a completed Device Details spreadsheet. Transmit all completed files through the CESG.
IMDRF Table of Contents Format Is Also Mandatory
The REP transition coincides with Health Canada’s adoption of the International Medical Device Regulators Forum (IMDRF) Table of Contents (ToC) format for MDL submissions. Health Canada published this requirement on November 11, 2025, and it came into force on February 2, 2026. Submissions must now follow a specific folder structure and file naming convention aligned with global regulatory standards used in the EU, Australia, and other major markets.
Manufacturers already filing in multiple jurisdictions may recognise the IMDRF ToC structure. Those filing in Canada for the first time, or companies accustomed to the previous unstructured format, will need extra preparation time to build dossiers to the ToC standard before submission.
What This Means for Your Business
Confirm your Company ID first
The most immediate priority is confirming that your Company ID and Contact IDs are already in place. Health Canada has been issuing final Company XML files to active companies. If you received that file, review it for accuracy and retain it; you need those IDs for all future transactions. If you have not yet completed company enrolment, start that process before any application work.
Update your templates and processes
For companies preparing new or amendment applications, internal regulatory teams and external representatives must be familiar with the REP XML template set and CESG transmission requirements. Health Canada will reject applications built against the old PDF format at administrative screening. Resubmitting from scratch adds time to what is already a measured review timeline.
Verify your representative is REP-ready
Companies that rely on a Canadian regulatory agent or importer for submissions should confirm their representative is already operating within the REP framework. A representative who is not set up for REP will create delays that fall directly on the manufacturer’s market authorisation timeline.
Treat REP compliance as a prerequisite, not a final step
The broader implication is that REP standardises what Health Canada sees at intake. Well-structured submissions with complete REP files move through screening faster. Incomplete or non-compliant packages get returned earlier in the process. Quality Smart Solutions advises manufacturers to build REP compliance into submission preparation from the start, not as an afterthought.
Key Takeaways
- REP has been mandatory for Class II, III, and IV MDL applications since January 2026. Health Canada no longer accepts PDF forms or email submissions.
- Manufacturers must obtain a Company ID via the CO Template before any other REP step can proceed.
- A Dossier ID is required for each device or device family. Request it before filing a regulatory transaction.
- All submissions must go through the CESG using structured XML templates.
- The IMDRF Table of Contents format is mandatory for MDL dossiers as of February 2, 2026.
Frequently Asked Questions
If my company already has an active MDL, do I need to do anything right now?
Existing licences remain valid. However, if Health Canada issued a final Company XML file to your organisation, review it and retain it. It contains the Company ID and Contact IDs you will need for any future regulatory transaction, including amendments, renewals, and responses to Health Canada requests. If no filings are planned, no immediate action is required. The moment any filing becomes necessary, REP enrolment must already be complete.
What happens if I submit an MDL application using the old PDF form after January 2026?
Health Canada will reject it. MDL submissions for Class II, III, and IV devices filed outside the REP framework — by email, on physical media, or using legacy PDF forms instead of required XML templates — will not pass administrative screening. Health Canada returns the application without review. The manufacturer must then refile correctly, losing any time already spent in the queue.
Do all medical devices fall under mandatory REP, or are there exceptions?
The mandatory REP requirement covers Class II, III, and IV device licence applications; new applications, amendments, and all related regulatory transactions, including responses to deficiency letters and unsolicited information submissions. Class I devices, which require only a Medical Device Establishment Licence (MDEL) rather than an MDL, fall outside this requirement. Manufacturers with devices across multiple classes should confirm the classification of each device before determining which submissions are in scope.
Next Steps for REP Compliance
Manufacturers who have not yet completed company enrolment in REP should treat that as their first priority. The sequence matters — Company ID, then Dossier ID, then application preparation — and each step takes time. For companies navigating the REP framework for the first time, or those managing multiple devices across device families, the preparation required before a single application can be filed is more involved than the previous process.
To discuss where your organisation stands and what needs to be done before your next MDL submission, contact Quality Smart Solutions or learn more about medical device licensing services for Canada.
